New Research Offers Insights on Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Landscape and Therapeutic Assessment in H1 2018


Published on : Feb 20, 2018

Albany, New York, February 20, 2018: Attention Deficit Hyperactivity Disorder, ADHD, is one of the most common disorders that develop in children. If left untreated it can have long-term adverse effects into adolescence and adulthood. The latest pipeline has been launched and added to Market Research Hub’s vast portfolio of research reports. The report is titled as “Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H1 2018”, which provides comprehensive data on the therapeutic development for attention deficit hyperactivity disorder along with the analysis based on various stages of development, drug profiles, route of administration (RoA), mechanism of action (MoA) and molecule type.

Firstly, the report starts with the brief introduction to Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder (ADHD) affects children and teens and can continue into adulthood. ADHD is the most commonly diagnosed mental disorder in children. Symptoms of ADHD described in the study include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Available treatments, such as medication, counseling, lifestyle changes or a combination of these treatments help in reducing symptoms with improved functioning of the patient. Apart from that, children between the ages 4-17 been diagnosed with ADHD, with drug therapy is the commonly prescribed treatment by the physicians. As per the report, major drug treatment includes analeptics.

To elaborate further, the pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The guide is built using primary data and facts sourced from global markets direct proprietary records, company & university websites, clinical trial registries, SEC filings, conferences, investor presentations and featured press releases from university sites along with industry-specific third party sources. Additionally, various dynamic tracking methods ensure that the most recent developments are captured on a real-time basis. Moreover, this pipeline assessment helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.

Some of the prime companies involved in the therapeutics development of ADHD include APeT Holding BV, BCWorld Pharm Co Ltd, Collegium Pharmaceutical Inc, Reviva Pharmaceuticals Inc, Amarantus Bioscience Holdings Inc, Otsuka Pharmaceutical Co Ltd, Curemark LLC, Arcturus Therapeutics Ltd, NeuroDerm Ltd, RespireRx Pharmaceuticals Inc, Aevi Genomic Medicine Inc, Taisho Pharmaceutical Holdings Co Ltd, Merck & Co Inc, SK Biopharmaceuticals Co Ltd, BioHealthonomics Inc, Sunovion Pharmaceuticals Inc, Heptares Therapeutics Ltd, Noven Pharmaceuticals Inc, 4P-Pharma SAS, Novartis AG, Tris Pharma Inc, Cingulate Therapeutics LLC

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1555701

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top